BDX · Company research
Becton, Dickinson and Co. (BDX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
34records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Catholic Medical Mission Board and Church of the Brethren to mark partnership with ribbon-cutting | Catholic Medical Mission Board (CMMB) opened its new Distribution Center at the Brethren Service Center in New Windsor, Maryland on October 22, 2026. The relocation expands CMMB's operational capacity for its Access to Medicines Program, which distributed $243.5 million worth of medicines and medical supplies to 64 partners across 28 countries in 2025. The partnership strengthens both organizations' humanitarian efforts. | View source ↗ | GlobeNewswire Inc. | Oct 20, 2026 | bullish | 1 | 1 |
| BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients | Becton, Dickinson and Company (BD) announced positive nine-month results from the AGILITY trial for its Revello Vascular Covered Stent in treating iliac artery disease. The trial met its primary endpoint with a 2.8% failure rate, 97.2% primary patency, and 98.3% freedom from clinically driven target lesion revascularization. The device remains investigational in the U.S. with clinical follow-up continuing through 36 months. The global iliac stent market is projected to grow at a 6.5% CAGR through 2033. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients | Becton, Dickinson and Company (BD) announced positive nine-month results from the AGILITY trial for its Revello Vascular Covered Stent in treating iliac artery disease. The trial met its primary endpoint with a 2.8% failure rate, 97.2% primary patency, and 98.3% freedom from clinically driven target lesion revascularization. The device remains investigational in the U.S. with clinical follow-up continuing through 36 months. The global iliac stent market is projected to grow at a 6.5% CAGR through 2033. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Will U.S. Manufacturing Deal Change Becton Dickinson (BDX) Stock Narrative - Simply Wall Street | Will U.S. Manufacturing Deal Change Becton Dickinson (BDX) Stock Narrative Simply Wall Street | View source ↗ | Simply Wall Street | Oct 15, 2026 | neutral | 0 | 0.6 |
| Becton, Dickinson and Company (BDX) Stock Price, News, Quote & History - Yahoo! Finance Canada | Becton, Dickinson and Company (BDX) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight | The global microbiology testing market is projected to grow from USD 6.3 billion in 2025 to USD 13.7 billion by 2034, driven by increasing infectious disease prevalence, antimicrobial resistance concerns, and stringent regulatory requirements. North America leads with 42% market share, while Asia-Pacific is expected to record the fastest growth. Key drivers include technological advancements in molecular diagnostics, laboratory automation, and expanding clinical diagnostic infrastructure. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bullish | 1 | 1 |
| Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight | The global microbiology testing market is projected to grow from USD 6.3 billion in 2025 to USD 13.7 billion by 2034, driven by increasing infectious disease prevalence, antimicrobial resistance concerns, and stringent regulatory requirements. North America leads with 42% market share, while Asia-Pacific is expected to record the fastest growth. Key drivers include technological advancements in molecular diagnostics, laboratory automation, and expanding clinical diagnostic infrastructure. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bullish | 1 | 1 |
| Becton Dickinson (BDX) Grew Revenue 5.4% While Earnings Fell 34.3%. Why Did Profit Fall So Much Further? - Yahoo Finance | Becton Dickinson (BDX) Grew Revenue 5.4% While Earnings Fell 34.3%. Why Did Profit Fall So Much Further? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| Weekly Recap: $19B U.S. investment and undisclosed agreement impact - TradingView | Weekly Recap: $19B U.S. investment and undisclosed agreement impact TradingView | View source ↗ | TradingView | Oct 12, 2026 | neutral | 0 | 0.6 |
| Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report? | Becton Dickinson (BDX) has demonstrated a strong earnings-beat streak, with an average surprise of 3.78% over the last two quarters. The company currently has a positive Earnings ESP of +0.21% combined with a Zacks Rank #3 (Hold), suggesting another potential earnings beat in its November 5, 2026 report. Stocks with this combination historically beat consensus estimates nearly 70% of the time. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report? | Becton Dickinson (BDX) has demonstrated a strong earnings-beat streak, with an average surprise of 3.78% over the last two quarters. The company currently has a positive Earnings ESP of +0.21% combined with a Zacks Rank #3 (Hold), suggesting another potential earnings beat in its November 5, 2026 report. Stocks with this combination historically beat consensus estimates nearly 70% of the time. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Becton Dickinson (BDX) Posts Strong AGILITY Trial Results, Is The Stock Still Below Fair Value? - Yahoo Finance | Becton Dickinson (BDX) Posts Strong AGILITY Trial Results, Is The Stock Still Below Fair Value? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| About 260,000 women died from pregnancy-related causes in 2023. Leaders urge wider monitoring. - Stock Titan | About 260,000 women died from pregnancy-related causes in 2023. Leaders urge wider monitoring. Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| BDX Expands U.S. Manufacturing With $19B Healthcare Investment | Becton, Dickinson and Company (BD) announced a landmark partnership with the U.S. Government to invest $19 billion in domestic manufacturing expansion, including $3 billion toward manufacturing capacity. The company aims to increase domestically supplied essential medical consumables to 80% and manufacture all U.S.-used needles domestically with American-made steel. The agreement provides tariff protection on covered products, though financial impact remains unquantified pending finalization of tariff rates and implementation timing. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| BDX Expands U.S. Manufacturing With $19B Healthcare Investment | Becton, Dickinson and Company (BD) announced a landmark partnership with the U.S. Government to invest $19 billion in domestic manufacturing expansion, including $3 billion toward manufacturing capacity. The company aims to increase domestically supplied essential medical consumables to 80% and manufacture all U.S.-used needles domestically with American-made steel. The agreement provides tariff protection on covered products, though financial impact remains unquantified pending finalization of tariff rates and implementation timing. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| BDX Expands U.S. Manufacturing With $19B Healthcare Investment - TradingView | BDX Expands U.S. Manufacturing With $19B Healthcare Investment TradingView | View source ↗ | TradingView | Oct 7, 2026 | neutral | 0 | 0.6 |
| More than 97% of treated arteries stayed open after nine months in BD's stent study - Stock Titan | More than 97% of treated arteries stayed open after nine months in BD's stent study Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Becton Dickinson and Co Share Price - BDX, RNS News, Articles, Quotes, & Charts (NYSE:BDX) - Proactive financial news | Becton Dickinson and Co Share Price - BDX, RNS News, Articles, Quotes, & Charts (NYSE:BDX) Proactive financial news | View source ↗ | Proactive financial news | Oct 7, 2026 | neutral | 0 | 0.6 |
| BDX Expands U.S. Manufacturing With $19B Healthcare Investment - TradingView | BDX Expands U.S. Manufacturing With $19B Healthcare Investment TradingView | View source ↗ | TradingView | Oct 7, 2026 | neutral | 0 | 0.6 |
| 2 US Value Stocks to Buy at a Discount - Morningstar | 2 US Value Stocks to Buy at a Discount Morningstar | View source ↗ | Morningstar | Oct 7, 2026 | neutral | 0 | 0.6 |
| A new leader takes charge of BD’s Surgery business immediately - Stock Titan | A new leader takes charge of BD’s Surgery business immediately Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| A medical supplier plans to make all its U.S. needles at home with American steel. - Stock Titan | A medical supplier plans to make all its U.S. needles at home with American steel. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Zacks Industry Outlook Highlights McKesson, Cardinal Health, Becton, Dickinson, Merit Medical Systems and ProDex | The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, and technology adoption, with the global market expected to reach $318.77 billion by 2031. However, tariffs, commodity inflation, and policy-driven pricing changes present headwinds. Five key stocks—McKesson, Cardinal Health, Becton Dickinson, Merit Medical Systems, and ProDex—are highlighted as well-positioned to capitalize on favorable industry trends through 2026. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.8 | 1 |
| Zacks Industry Outlook Highlights McKesson, Cardinal Health, Becton, Dickinson, Merit Medical Systems and ProDex | The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, and technology adoption, with the global market expected to reach $318.77 billion by 2031. However, tariffs, commodity inflation, and policy-driven pricing changes present headwinds. Five key stocks—McKesson, Cardinal Health, Becton Dickinson, Merit Medical Systems, and ProDex—are highlighted as well-positioned to capitalize on favorable industry trends through 2026. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.8 | 1 |
| Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight | The global liver cancer diagnostics market is projected to grow from USD 10.5 billion in 2025 to USD 19.8 billion by 2034, driven by rising hepatocellular carcinoma incidence, increasing chronic liver disease prevalence, and advances in diagnostic technologies including liquid biopsy, AI-assisted imaging, and blood-based biomarkers. North America leads the market with 41% share, while Asia-Pacific is expected to be the fastest-growing region. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight | The global liver cancer diagnostics market is projected to grow from USD 10.5 billion in 2025 to USD 19.8 billion by 2034, driven by rising hepatocellular carcinoma incidence, increasing chronic liver disease prevalence, and advances in diagnostic technologies including liquid biopsy, AI-assisted imaging, and blood-based biomarkers. North America leads the market with 41% share, while Asia-Pacific is expected to be the fastest-growing region. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| 5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve | The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, AI automation, and aging demographics. The global medical supplies market is expected to reach $318.77 billion by 2031 with a 10% CAGR. However, tariffs, commodity inflation, and pharmaceutical pricing changes remain headwinds. Key industry players show mixed near-term prospects with the industry trading at favorable valuations compared to broader markets. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.6 | 1 |
| 5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve | The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, AI automation, and aging demographics. The global medical supplies market is expected to reach $318.77 billion by 2031 with a 10% CAGR. However, tariffs, commodity inflation, and pharmaceutical pricing changes remain headwinds. Key industry players show mixed near-term prospects with the industry trading at favorable valuations compared to broader markets. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.6 | 1 |
| Here's Why You Should Retain BDX Stock in Your Portfolio for Now - Yahoo Finance | Here's Why You Should Retain BDX Stock in Your Portfolio for Now Yahoo Finance | View source ↗ | Yahoo Finance | Sep 28, 2026 | neutral | 0 | 0.6 |
| A Lenovo executive is set to lead BD’s AI work - Stock Titan | A Lenovo executive is set to lead BD’s AI work Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks - Yahoo Finance | Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks Yahoo Finance | View source ↗ | Yahoo Finance | Aug 21, 2026 | neutral | 0 | 0.6 |
| Becton Dickinson (BDX) Stock Sees Modest Fair Value Lift After Mixed Analyst Views - Yahoo Finance | Becton Dickinson (BDX) Stock Sees Modest Fair Value Lift After Mixed Analyst Views Yahoo Finance | View source ↗ | Yahoo Finance | Aug 9, 2026 | neutral | 0 | 0.6 |
| Becton, Dickinson shares rise as fresh Buy initiation adds to improving post-spin outlook | BDX Stock News - Quiver Quantitative | Becton, Dickinson shares rise as fresh Buy initiation adds to improving post-spin outlook | BDX Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 28, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Retain BDX Stock in Your Portfolio Now - Yahoo Finance | Here's Why You Should Retain BDX Stock in Your Portfolio Now Yahoo Finance | View source ↗ | Yahoo Finance | Jun 16, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.